Novo Ventures invests millions in Bavarian Nordic rival

London-based biotech company Reviral has raised USD 55 million for the continued development of its phase II candidate against the respiratory disease RSV. Novo Ventures is among the investors.

Photo: Novo Holdings/PR

The competition is intensifying on the potential billion-dollar market for treatment of the respiratory disease RSV and now, Novo Holdings also sets the ball rolling.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Ambu credits MDR milestone to fastidiousness

All of Medtech firm Ambu’s products already live up to the new EU rules for medical devices, something the firm attributes to a good sense of how much effort living up to the new legislation would require.

China approves Y-mabs drug

Y-mabs’ cancer treatment Danyelza, which is currently licensed to Sciclones, has been approved by the Chinese authorities. Y-mabs will receive double-digit sales royalties.

Further reading

Latest news

See all jobs